Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Postapproval Observational Studies of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation.

× No keyword cloud information.

13 in total

1. Introduction of Non-Vitamin K Antagonist Anticoagulants Strongly Increased the Rate of Anticoagulation in Hospitalized Geriatric Patients with Atrial Fibrillation.

Authors: Marija Djukic; Larissa Maria Braun; Steffen Unkel; Claudius Jacobshagen; Roland Nau
Journal: Drugs Aging Date: 2018-09 Impact factor: 3.923

2. The representativeness of direct oral anticoagulant clinical trials to hospitalized patients with atrial fibrillation.

Authors: Laura Fanning; Jenni Ilomäki; J Simon Bell; Pēteris Dārziņš
Journal: Eur J Clin Pharmacol Date: 2017-07-27 Impact factor: 2.953

3. Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction.

Authors: Ahsan A Khan; Gregory Y H Lip
Journal: Ann Transl Med Date: 2017-12

Review 4. Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction.

Authors: Tatjana S Potpara; Charles J Ferro; Gregory Y H Lip
Journal: Nat Rev Nephrol Date: 2018-03-26 Impact factor: 28.314

5. Comparative risks of bleeding, ischemic stroke and mortality with direct oral anticoagulants versus phenprocoumon in patients with atrial fibrillation.

Authors: Mariam Ujeyl; Ingrid Köster; Hans Wille; Thomas Stammschulte; Rebecca Hein; Sebastian Harder; Ursula Gundert-Remy; Julian Bleek; Peter Ihle; Helmut Schröder; Gerhard Schillinger; Anette Zawinell; Ingrid Schubert
Journal: Eur J Clin Pharmacol Date: 2018-06-16 Impact factor: 2.953

Review 6. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis.

Authors: José A López-López; Jonathan A C Sterne; Howard H Z Thom; Julian P T Higgins; Aroon D Hingorani; George N Okoli; Philippa A Davies; Pritesh N Bodalia; Peter A Bryden; Nicky J Welton; William Hollingworth; Deborah M Caldwell; Jelena Savović; Sofia Dias; Chris Salisbury; Diane Eaton; Annya Stephens-Boal; Reecha Sofat
Journal: BMJ Date: 2017-11-28

7. Impact of the Health Insurance Coverage Policy on Oral Anticoagulant Prescription among Patients with Atrial Fibrillation in Korea from 2014 to 2016.

Authors: Young-Jin Ko; Seonji Kim; Kyounghoon Park; Minsuk Kim; Bo Ram Yang; Mi-Sook Kim; Joongyub Lee; Byung-Joo Park
Journal: J Korean Med Sci Date: 2018-05-09 Impact factor: 2.153

Review 8. Antithrombotic therapies for elderly patients: handling problems originating from their comorbidities.

Authors: Masahisa Arahata; Hidesaku Asakura
Journal: Clin Interv Aging Date: 2018-09-11 Impact factor: 4.458

9. A Multilevel Analysis of Real-World Variations in Oral Anticoagulation Initiation for Atrial Fibrillation in Valencia, a European Region.

Authors: Aníbal García-Sempere; Daniel Bejarano-Quisoboni; Julián Librero; Clara L Rodríguez-Bernal; Salvador Peiró; Gabriel Sanfélix-Gimeno
Journal: Front Pharmacol Date: 2017-08-24 Impact factor: 5.810

10. Non-bleeding Adverse Events with the Use of Direct Oral Anticoagulants: A Sequence Symmetry Analysis.

Authors: Géric Maura; Cécile Billionnet; Joël Coste; Alain Weill; Anke Neumann; Antoine Pariente
Journal: Drug Saf Date: 2018-09 Impact factor: 5.606